Baidu
map

Nature:重编程细胞同源移植也会发生排斥反应

2011-06-17 MedSci原创 MedSci原创

6月9日出版的自然杂志继5月刊发加州大学圣地亚哥分校的研究人员有关诱导多能干细胞(iPSCs)论文,再次刊登有关该研究的一篇快报,并予以评论,称研究人员在小鼠中证实将诱导多能干细胞(iPSCs)分化生成的多种组织移植至动物体内会产生快速的免疫排斥反应,即便iPSCs的起源细胞来自于移植小鼠本身。一直以来,大多数科学家们都认为来自于个人自身组织的重编程细胞能够被安全地移植到同一个体体内并能避免排斥反

6月9日出版的自然杂志继5月刊发加州大学圣地亚哥分校的研究人员有关诱导多能干细胞(iPSCs)论文,再次刊登有关该研究的一篇快报,并予以评论,称研究人员在小鼠中证实将诱导多能干细胞(iPSCs)分化生成的多种组织移植至动物体内会产生快速的免疫排斥反应,即便iPSCs的起源细胞来自于移植小鼠本身。一直以来,大多数科学家们都认为来自于个人自身组织的重编程细胞能够被安全地移植到同一个体体内并能避免排斥反应。这一研究结果或将对再生医学领域造成巨大的震动。

领导这一研究的是加州大学圣地亚哥分校的徐洋(Yang Xu)教授,其1989年毕业于武汉大学,之后赴美求学,获得哈佛大学的博士学位,并在麻省理工学院完成博士后的研究工作,目前任加州大学圣地亚哥分校生物系终身正教

原文,请点击

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879093, encodeId=459918e9093b9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 26 13:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262954, encodeId=52241262954c0, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jun 19 05:23:00 CST 2011, time=2011-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532128, encodeId=2cb8153212859, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sun Jun 19 05:23:00 CST 2011, time=2011-06-19, status=1, ipAttribution=)]
    2012-02-26 hb2008ye
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879093, encodeId=459918e9093b9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 26 13:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262954, encodeId=52241262954c0, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jun 19 05:23:00 CST 2011, time=2011-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532128, encodeId=2cb8153212859, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sun Jun 19 05:23:00 CST 2011, time=2011-06-19, status=1, ipAttribution=)]
    2011-06-19 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879093, encodeId=459918e9093b9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 26 13:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262954, encodeId=52241262954c0, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jun 19 05:23:00 CST 2011, time=2011-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532128, encodeId=2cb8153212859, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sun Jun 19 05:23:00 CST 2011, time=2011-06-19, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map